Information  X 
Enter a valid email address

Summit Therapeutics PLC Ord 1P (SUMM)

Related News

11-Oct-2019 01:52 PM

Summit Therapeutics losses deepen on higher R&D spend

Pharmaceutical company Summit Therapeutics posted a deeper second-quarter loss amid a rise in R&D spending. Pre-tax losses for the three months through September amounted to $7.6m, compared to losses of $6.2m on-year. For the first half, pre-tax losses
27-Mar-2019 01:22 PM

Summit Therapeutics swings to profit

Summit Therapeutics swung to an annual profit as it continued to develop its antibiotic portfolio. Pre-tax profit for the year through amounted to £5.0m, compared to a loss of £24.0m on-year. Revenue more than tripled to £43.0m, wi
11-Dec-2018 01:43 PM

Summit Therapeutics losses deepen as expenses rise

Summit Therapeutics posted a deeper third-quarter loss underpinned by higher R&D spending and expenses related to payments to executives. Pre-tax losses for the three months through September amounted to £9.4m, compared to losses of £2.3m on-
05-Jun-2018 01:31 PM

Summit Therapeutics losses deepen on higher R&D spend

Rare and infectious disease specialist Summit Therapeutics said its first-quarter losses deepened after it upped R&D spending. Pre-tax losses amounted to £6.8m, compared to a loss in the previous corresponding period of £6.0m. Revenue more
21-Dec-2017 09:20 AM

Summit enters licence agreement in Latin America

Summit Therapeutics, a drug discovery and development company, has entered into an exclusive licence and commercialisation agreement granting Eurofarma Laboratorios rights in Latin America to Summit's precision antibiotic ridinilazole in development
04-Dec-2017 01:33 PM

Summit schedules interim results announcement

Summit Therapeutics has confirmed that the Company intends to announce its third quarter and nine months results to 31 October on 6 December. At 1:33pm: (LON:SUMM) Summit Therapeutics PLC share price was 0p at 180p Story provided by StockMarketWire
22-Nov-2017 01:33 PM

Summit to participate in US investor conferences

Summit Therapeutics has confirmed that it will participating in two upcoming investor conferences in New York City. These include: - 29th Annual Piper Jaffray Healthcare Conference - November 28, fireside chat at 1:30pm EST - Oppenheimer Rare Disease D
20-Nov-2017 01:14 PM

Summit completes initial PhaseOut DMD trial

Summit Therapeutics said it has completed the initial 24-weeks of dosing of ezutromid in patients with DMD in its Phase 2 clinical trial called PhaseOut DMD. The Company added that it continues to expect to report results from this initial 24-week dosing
09-Nov-2017 01:42 PM

Summit to present at Duchenne Conference

Summit Therapeutics has confirmed that new preclinical data shows a positive effect of utrophin modulation on improving muscle health in DMD. The Company also announced that it and collaborators from the University of Oxford will highlight the potential
06-Nov-2017 01:41 PM

Summit inks revenue sharing agreement with Wellcome Trust

Summit Therapeutics confirmed that the Company has entered into an equity and revenue sharing agreement with the Wellcome Trust, covering potential future revenues generated by ridinilazole. "The Wellcome Trust has played a crucial role in supportin
09-Oct-2017 01:11 PM

Summit highlights Microbiome Preservation during Ridinilazole treatment

Summit has announced that at ID Week 2017, it presented further positive gut microbiome data of ridinilazole from its exploratory Phase 2 clinical trial. As was previously reported, the Company's novel and highly selective antibiotic, ridinilazole,
04-Oct-2017 01:03 PM

Summit to present at conference in Saint-Malo

Summit Therapeutics has confirmed that the Company and its collaborators will be presenting at the 22nd International Congress of the World Muscle Society, which is taking place in Saint-Malo, France, from 3-7 October. At 1:03pm: (LON:SUMM) Summit The
02-Oct-2017 01:29 PM

Summit to host R&D day

Summit Therapeutics has confirmed that the Company will host an R&D Day featuring presentations from experts in quantitative muscle image analysis and CDI alongside Summit's management on 11 October in New York City. At 1:29pm: (LON:SUMM) Summit
25-Sep-2017 01:46 PM

Summit joins cTAP

Summit Therapeutics confirmed that the Company has joined the Collaborative Trajectory Analysis Project ('cTAP') to support cTAP's mission of accelerating the development of drugs to treat DMD through a coalition of Duchenne clinical expert
11-Sep-2017 01:34 PM

Summit awarded Barda contract worth up to $62m

Summit Therapeutics has announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company a contract worth up to $62m. It said the funds will support the clinical and regulatory development of ridinilazole for the
05-Sep-2017 03:01 PM

Summit announces positive ridinilazole trial results

Summit Therapeutics has announced positive top-line data from an exploratory Phase 2 clinical trial that support ridinilazole as a highly selective and potent antibiotic product candidate for the treatment of Clostridium difficile infection (CDI). The Co
14-Jun-2017 01:28 PM

Summit losses fall

Summit Therapeutics has reported a loss for the three months ended 30 April 2017 of £4.8m, compared to a loss of £5.4m for the same period last year. The Company also confirmed a $22m milestone payment, triggered in May 2017, under the terms
13-Jun-2017 02:59 PM

Summit confirms date of Q1 results announcement

Summit Therapeutics said it will announce its financial results for the first quarter ended 30 April on 14 June. At 2:59pm: (LON:SUMM) Summit Therapeutics PLC share price was -5p at 172.5p Story provided by StockMarketWire.com...
05-Jun-2017 01:18 PM

Summit highlights benefits of ridinilazole at ASM Microbe

Summit Therapeutics has announced that the Company presented new preclinical data on ridinilazole were at ASM Microbe 2017, which was held in New Orleans, US from 1-5 June 2017. "These positive preclinical data presented at ASM Microbe highlight the
15-May-2017 01:06 PM

Summit completes PhaseOut DMD enrolment

Summit Therapeutics confirmed the the Company has completed enrolment in PhaseOut DMD, a Phase 2 proof of concept clinical trial of the utrophin modulator, ezutromid, in patients with DMD. PhaseOut DMD aims to provide proof of concept for ezutromid throu
30-Mar-2017 02:18 PM

Summit changes registered office

Summit Therapeutics has announced that the Company's registered office has changed to 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, UK with immediate effect. At 2:18pm: (LON:SUMM) Summit Therapeutics PLC share price was 0p at
27-Mar-2017 02:06 PM

Summit schedules FY results

Summit Therapeutics will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2017 on Wednesday, 29 March 2017. At 2:06pm: (LON:SUMM) Summit Therapeutics PLC share price was +5p at 207.5p Story provided by Sto
27-Mar-2017 01:53 PM

Summit to extend PhaseOut DMD clinical trial

Summit Therapeutics has confirmed that it will proceed with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial evaluating the utrophin modulator ezutromid, subject to regulatory approval. The Company said this follows an interim review
02-Feb-2017 02:10 PM

Summit to take part in investor conferences

Summit Therapeutics has announced that company management will participate in three upcoming investor conferences taking place in New York City in February. - Canaccord Genuity Rare Disease and BioPharma One-on-One Day - February 7, 2017 - BIO CEO & Inv
01-Feb-2017 01:36 PM

Summit outlines Phase 3 programme for ridinilazole

Summit Therapeutics has outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration ('FDA') and European Medicines Agency ('EMA'). With input fro
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t